Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Cellectis    ALCLS   FR0010425595

CELLECTIS

(ALCLS)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cellectis : A technical turn-around configuration

share with twitter share with LinkedIn share with facebook
share via e-mail
12/03/2019 | 04:23am EST
long trade
Live
Entry price : 13.04€ | Target : 14.5€ | Stop-loss : 12€ | Potential : 11.2%
The timing from a technical point of view appears attractive to go long in shares of Cellectis and to anticipate a trend reversal.
Investors have an opportunity to buy the stock and target the € 14.5.
Cellectis : Cellectis : A technical turn-around configuration
Strengths
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The group usually releases upbeat results with huge surprise rates.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses
  • Low profitability weakens the company.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart
Subsector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
CELLECTIS-9.42%643
-
IQVIA HOLDINGS INC.25.78%28 353
LONZA GROUP31.49%25 241
INCYTE CORPORATION50.53%20 618
SEATTLE GENETICS, INC.101.16%19 535
CELLTRION, INC.--.--%17 845
GALAPAGOS140.88%13 923
ALNYLAM PHARMACEUTICALS, IN..67.11%13 584
EXACT SCIENCES CORPORATION35.18%12 559
QIAGEN20.99%9 440
IONIS PHARMACEUTICALS, INC.16.37%8 849
More Results

Gallien Girardot
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (EUR)
Sales 2019 19,6 M
EBIT 2019 -108 M
Net income 2019 -94,7 M
Finance 2019 219 M
Yield 2019 -
P/E ratio 2019 -4,34x
P/E ratio 2020 -5,15x
EV / Sales2019 18,4x
EV / Sales2020 7,60x
Capitalization 580 M
Upcoming event on CELLECTIS
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 25,05  €
Last Close Price 13,66  €
Spread / Highest target 86,7%
Spread / Average Target 83,4%
Spread / Lowest Target 80,1%
EPS Revisions
Managers
NameTitle
André Choulika Chairman & Chief Executive Officer
Elsy Boglioli Chief Operating Officer
Eric Dutang Chief Financial Officer
Philippe Duchateau Chief Scientific Officer
Stephane Depil Chief Medical Officer, EVP-Research & Development